Top

Published in:

Open Access 01-12-2023 | Research

Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study

Authors: Jinluan Chen, Banafsheh Arshi, Komal Waqas, Tianqi Lu, Daniel Bos, M. Arfan Ikram, André G. Uitterlinden, Maryam Kavousi, M. Carola Zillikens

Published in: Cardiovascular Diabetology | Issue 1/2023

Abstract

Background

Advanced glycation end products (AGEs) have been linked to cardiovascular disease (CVD), especially coronary heart disease (CHD), but their role in CVD pathogenesis remains unclear. Therefore, we investigated cross-sectional associations of skin AGEs with subclinical atherosclerosis, arterial stiffness, and hypertension after confirming their relation with CHD.

Methods

In the population-based Rotterdam Study, skin AGEs were measured as skin autofluorescence (SAF). Prevalent MI was obtained from digital medical records. Carotid plaques, carotid intima-media thickness (IMT), coronary artery calcification (CAC), pulse wave velocity (PWV), and hypertension were assessed. Associations of SAF with endophenotypes were investigated in logistic and linear regression models adjusting for common cardiovascular risk factors. Effect modification by sex, diabetes mellitus, and chronic kidney disease (CKD) was tested.

Results

3001 participants were included (mean age 73 (SD 9) years, 57% women). One unit higher SAF was associated with the presence of carotid plaques (OR 1.2 (0.92, 1.57)), a higher max IMT (0.08 SD (0.01, 0.15)), higher CAC (OR 2.2 (1.39, 3.48)), and PWV (0.09 SD (0.01, 0.16)), but not with hypertension (OR 0.99 (0.81, 1.21)). The associations with endophenotypes were more pronounced in men and participants with diabetes or CKD with significant interactions.

Conclusions

Previously documented associations between SAF and CVD, also found in our study, may be explained by the endophenotypes atherosclerosis and arterial stiffness, especially in men and individuals with diabetes or CKD, but not by hypertension. Longitudinal studies are needed to replicate these findings and to test if SAF is an independent risk factor or biomarker of CVD.

Trial registration: The Rotterdam Study has been entered into the Netherlands National Trial Register (NTR; www.trialregister.nl) and the WHO International Clinical Trials Registry Platform (ICTRP; www.who.int/ictrp/network/primary/en/) under shared catalogue number NTR6831.

Available only for authorised users

Collaborators GCD. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in;195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017 (vol 392, pg 1736, 2018). Lancet. 2018;392(10160):2170.

Fuchs A, Kuhl JT, Sigvardsen PE, Afzal S, Knudsen AD, Moller MB, et al. Subclinical coronary atherosclerosis and risk for myocardial infarction in a danish cohort : a prospective observational cohort study. Ann Intern Med. 2023;176(4):433–42.CrossRefPubMed

Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia. 2001;44(2):129–46.CrossRefPubMed

Rajaobelina K, Helmer C, Velayoudom-Cephise FL, Nov S, Farges B, Pupier E, et al. Progression of skin autofluorescence of AGEs over 4 years in patients with type 1 diabetes. Diabetes Metab Res Rev. 2017. https://doi.org/10.1002/dmrr.2917.CrossRefPubMed

Koetsier M, Lutgers HL, de Jonge C, Links TP, Smit AJ, Graaff R. Reference values of skin autofluorescence. Diabetes Technol The. 2010;12(5):399–403.CrossRef

Baumann M, Richart T, Sollinger D, Pelisek J, Roos M, Kouznetsova T, et al. Association between carotid diameter and the advanced glycation end product N-epsilon-carboxymethyllysine (CML). Cardiovasc Diabetol. 2009;8:45.PubMedCentralCrossRefPubMed

Sakata N, Imanaga Y, Meng J, Tachikawa Y, Takebayashi S, Nagai R, et al. Immunohistochemical localization of different epitopes of advanced glycation end products in human atherosclerotic lesions. Atherosclerosis. 1998;141(1):61–75.CrossRefPubMed

Nakamura Y, Horii Y, Nishino T, Shiiki H, Sakaguchi Y, Kagoshima T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol. 1993;143(6):1649–56.PubMedCentralPubMed

Sabbatinelli J, Castiglione S, Macri F, Giuliani A, Ramini D, Vinci MC, et al. Circulating levels of AGEs and soluble RAGE isoforms are associated with all-cause mortality and development of cardiovascular complications in type 2 diabetes: a retrospective cohort study. Cardiovasc Diabetol. 2022;21(1):95.PubMedCentralCrossRefPubMed

10.

Majchrzak C, Cougnard-Gregoire A, Le-Goff M, Feart C, Delcourt C, Reydit M, et al. Skin autofluorescence of advanced glycation end-products and mortality in older adults: the roles of chronic kidney disease and diabetes. Nutr Metab Cardiovasc Dis. 2022;32(11):2526–33.CrossRefPubMed

11.

Martinez-Sanchez FD, Medina-Urrutia AX, Jorge-Galarza E, Martinez-Alvarado MDR, Reyes-Barrera J, Osorio-Alonso H, et al. Effect of metabolic control on recurrent major adverse cardiovascular events and cardiovascular mortality in patients with premature coronary artery disease: results of the Genetics of Atherosclerotic Disease study. Nutr Metab Cardiovasc Dis. 2022;32(9):2227–37.CrossRefPubMed

12.

Monnier VM, Sun W, Gao X, Sell DR, Cleary PA, Lachin JM, et al. Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovasc Diabetol. 2015;14:118.PubMedCentralCrossRefPubMed

13.

Nathan DM, Lachin J, Cleary P, Orchard T, Brillon DJ, Backlund JY, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med. 2003;348(23):2294–303.CrossRefPubMed

14.

Monnier VM, Bautista O, Kenny D, Sell DR, Fogarty J, Dahms W, et al. Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type 1 diabetes: relevance of glycated collagen products versus HbA1c as markers of diabetic complications. DCCT skin collagen ancillary study group. diabetes control and complications trial. Diabetes. 1999;48(4):870–80.CrossRefPubMed

15.

Borderie G, Foussard N, Larroumet A, Blanco L, Barbet-Massin MA, Ducos C, et al. The skin autofluorescence of advanced glycation end-products relates to the development of foot ulcers in type 2 diabetes: a longitudinal observational study. J Diabetes Complicat. 2023;37(10):108595.CrossRef

16.

Cavero-Redondo I, Soriano-Cano A, Alvarez-Bueno C, Cunha PG, Martinez-Hortelano JA, Garrido-Miguel M, et al. Skin autofluorescence-indicated advanced glycation end products as predictors of cardiovascular and all-cause mortality in high-risk subjects: a systematic review and meta-analysis. J Am Heart Assoc. 2018. https://doi.org/10.1161/JAHA.118.009833.CrossRefPubMedCentralPubMed

17.

van Waateringe RP, Fokkens BT, Slagter SN, van der Klauw MM, van Vliet-Ostaptchouk JV, Graaff R, et al. Skin autofluorescence predicts incident type 2 diabetes, cardiovascular disease and mortality in the general population. Diabetologia. 2019;62(2):269–80.CrossRefPubMed

18.

Kunimoto M, Yokoyama M, Shimada K, Matsubara T, Aikawa T, Ouchi S, et al. Relationship between skin autofluorescence levels and clinical events in patients with heart failure undergoing cardiac rehabilitation. Cardiovasc Diabetol. 2021;20(1):208.PubMedCentralCrossRefPubMed

19.

Yoshioka K. Skin autofluorescence is a noninvasive surrogate marker for diabetic microvascular complications and carotid intima-media thickness in japanese patients with type 2 diabetes: a cross-sectional study. Diabetes Ther. 2018;9(1):75–85.CrossRefPubMed

20.

Watfa G, Soulis G, Tartagni E, Kearney-Schwartz A, Borghi C, Salvi P, et al. Relationship between tissue glycation measured by autofluorescence and pulse wave velocity in young and elderly non-diabetic populations. Diabetes Metab. 2012;38(5):413–9.CrossRefPubMed

21.

Hanssen N, Engelen L, Ferreira I, Scheijen J, Huijberts M, van Greevenbroek M, et al. Plasma advanced glycation end products are not associated with cardiovascular disease in individuals with or without type 2 diabetes: the Hoorn and CODAM studies. Diabetologia. 2012;55:S61.

22.

Gelzinsky J, Mayer O Jr, Seidlerova J, Materankova M, Mares S, Kordikova V, et al. Serum biomarkers, skin autofluorescence and other methods. Which parameter better illustrates the relationship between advanced glycation end products and arterial stiffness in the general population? Hypertens Res. 2021;44(5):518–27.CrossRefPubMed

23.

Kilhovd BK, Juutilainen A, Lehto S, Ronnemaa T, Torjesen PA, Birkeland KI, et al. High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men—a population-based 18-year follow-up study. Arterioscl Throm Vas. 2005;25(4):815–20.CrossRef

24.

Ikram MA, Brusselle G, Ghanbari M, Goedegebure A, Ikram MK, Kavousi M, et al. Objectives, design and main findings until 2020 from the Rotterdam study. Eur J Epidemiol. 2020;35(5):483–517.PubMedCentralCrossRefPubMed

25.

Meerwaldt R, Links T, Graaff R, Thorpe SR, Baynes JW, Hartog J, et al. Simple noninvasive measurement of skin autofluorescence. Ann Ny Acad Sci. 2005;1043:290–8.CrossRefPubMed

26.

Chen J, van der Duin D, Campos-Obando N, Ikram MA, Nijsten TEC, Uitterlinden AG, et al. Serum 25-hydroxyvitamin D(3) is associated with advanced glycation end products (AGEs) measured as skin autofluorescence: the Rotterdam study. Eur J Epidemiol. 2019;34(1):67–77.CrossRefPubMed

27.

Arsov S, Trajceska L, van Oeveren W, Smit AJ, Dzekova P, Stegmayr B, et al. Increase in skin autofluorescence and release of heart-type fatty acid binding protein in plasma predicts mortality of hemodialysis patients. Artif Organs. 2013;37(7):E114–22.CrossRefPubMed

28.

Lavielle A, Rubin S, Boyer A, Moreau K, Rajaobelina K, Combe C, et al. Skin autofluorescence in acute kidney injury. Crit Care. 2017. https://doi.org/10.1186/s13054-017-1598-0.CrossRefPubMedCentralPubMed

29.

Du T, Brandl B, Hauner H, Skurk T. Skin autofluorescence mirrors surrogate parameters of vascular aging: an enable study. Nutrients. 2023;15(7):1597. https://doi.org/10.3390/nu15071597 .

30.

Leening MJ, Kavousi M, Heeringa J, van Rooij FJ, Verkroost-van Heemst J, Deckers JW, et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam study. Eur J Epidemiol. 2012;27(3):173–85.PubMedCentralCrossRefPubMed

31.

Hollander M, Bots ML, Del Sol AI, Koudstaal PJ, Witteman JC, Grobbee DE, et al. Carotid plaques increase the risk of stroke and subtypes of cerebral infarction in asymptomatic elderly: the Rotterdam study. Circulation. 2002;105(24):2872–7.CrossRefPubMed

32.

van der Meer IM, Bots ML, Hofman A, del Sol AI, van der Kuip DA, Witteman JC. Predictive value of noninvasive measures of atherosclerosis for incident myocardial infarction: the Rotterdam study. Circulation. 2004;109(9):1089–94.CrossRefPubMed

33.

Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction—the Rotterdam study. Circulation. 1997;96(5):1432–7.CrossRefPubMed

34.

Vliegenthart R, Oudkerk M, Song B, van der Kuip DAM, Hofman A, Witteman JCM. Coronary calcification detected by electron-beam computed tomography and myocardial infarction—the Rotterdam coronary calcification study. Eur Heart J. 2002;23(20):1596–603.CrossRefPubMed

35.

Bos D, Leening MJG, Kavousi M, Hofman A, Franco OH, van der Lugt A, et al. Comparison of atherosclerotic calcification in major vessel beds on the risk of all-cause and cause-specific mortality the Rotterdam study. Circ-Cardiovasc Imag. 2015. https://doi.org/10.1161/CIRCIMAGING.115.003843.CrossRef

36.

Greenland P, Bonow RO, Brundage BH, Budoff MJ, Eisenberg MJ, Grundy SM, et al. ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on Electron Beam Computed Tomography) developed in collaboration with the Society of Atherosclerosis Imaging and Prevention and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2007;49(3):378–402.CrossRefPubMed

37.

Mattace-Raso FUS, van der Cammen TJM, Hofman A, van Popele NM, Bos ML, Schalekamp MADH, et al. Arterial stiffness and risk of coronary heart disease and stroke - The Rotterdam Study. Circulation. 2006;113(5):657–63.CrossRefPubMed

38.

van Herpt TTW, Ligthart S, Leening MJG, van Hoek M, Lieverse AG, Ikram MA, et al. Lifetime risk to progress from pre-diabetes to type 2 diabetes among women and men: comparison between American Diabetes Association and World Health Organization diagnostic criteria. BMJ Open Diabetes Res Care. 2020;8(2):e001529.PubMedCentralCrossRefPubMed

39.

Leening MJ, Ferket BS, Steyerberg EW, Kavousi M, Deckers JW, Nieboer D, et al. Sex differences in lifetime risk and first manifestation of cardiovascular disease: prospective population based cohort study. BMJ. 2014;349:g5992.PubMedCentralCrossRefPubMed

40.

Hangai M, Takebe N, Honma H, Sasaki A, Chida A, Nakano R, et al. Association of advanced glycation end products with coronary artery calcification in Japanese subjects with type 2 diabetes as assessed by skin autofluorescence. J Atheroscler Thromb. 2016;23(10):1178–87.PubMedCentralCrossRefPubMed

41.

Monnier VM, Sun WJ, Gao XY, Sell DR, Cleary PA, Lachin JM, et al. Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes. Cardiovasc Diabetol. 2015. https://doi.org/10.1186/s12933-015-0266-4.CrossRefPubMedCentralPubMed

42.

Saz-Lara A, Alvarez-Bueno C, Martinez-Vizcaino V, Notario-Pacheco B, Sequi-Dominguez I, Cavero-Redondo I. Are advanced glycation end products in skin associated with vascular dysfunction markers? A meta-analysis. Int J Environ Res Public Health. 2020;17(18):6936.PubMedCentralCrossRefPubMed

43.

Birukov A, Cuadrat R, Polemiti E, Eichelmann F, Schulze MB. Advanced glycation end-products, measured as skin autofluorescence, associate with vascular stiffness in diabetic, pre-diabetic and normoglycemic individuals: a cross-sectional study. Cardiovasc Diabetol. 2021;20(1):110.PubMedCentralCrossRefPubMed

44.

Harja E, Bu DX, Hudson BI, Chang JS, Shen X, Hallam K, et al. Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice. J Clin Invest. 2008;118(1):183–94.CrossRefPubMed

45.

Stirban A, Gawlowski T, Roden M. Vascular effects of advanced glycation endproducts: clinical effects and molecular mechanisms. Mol Metab. 2014;3(2):94–108.CrossRefPubMed

46.

Brüel A, Oxlund H. Changes in biomechanical properties, composition of collagen and elastin, and advanced glycation endproducts of the rat aorta in relation to age. Atherosclerosis. 1996;127(2):155–65.CrossRefPubMed

47.

Rabbani N, Godfrey L, Xue MZ, Shaheen F, Geoffrion M, Milne R, et al. Glycation of LDL by methylglyoxal increases arterial atherogenicity a possible contributor to increased risk of cardiovascular disease in diabetes. Diabetes. 2011;60(7):1973–80.PubMedCentralCrossRefPubMed

48.

Ren XM, Ren LQ, Wei Q, Shao H, Chen L, Liu NF. Advanced glycation end-products decreases expression of endothelial nitric oxide synthase through oxidative stress in human coronary artery endothelial cells. Cardiovasc Diabetol. 2017. https://doi.org/10.1186/s12933-017-0531-9.CrossRefPubMedCentralPubMed

49.

Mulder DJ, De Boer JF, Graaff R, De Vries R, Annema W, Lefrandt JD, et al. Skin autofluorescence is inversely related to hdl anti-oxidative capacity in type 2 diabetes mellitus. Atherosclerosis Supp. 2011;12(1):46.CrossRef

50.

Baumann M. Role of advanced glycation end products in hypertension and cardiovascular risk: human studies. J Am Soc Hypertens. 2012;6(6):427–35.CrossRefPubMed

51.

Botros N, Sluik D, van Waateringe RP, de Vries JHM, Geelen A, Feskens EJM. Advanced glycation end-products (AGEs) and associations with cardio-metabolic, lifestyle, and dietary factors in a general population: the NQplus study. Diabetes Metab Res Rev. 2017. https://doi.org/10.1002/dmrr.2892.CrossRefPubMed

52.

Franklin SS, Wt Gustin, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart study. Circulation. 1997;96(1):308–15.CrossRefPubMed

53.

Portegies ML, Mirza SS, Verlinden VJ, Hofman A, Koudstaal PJ, Swanson SA, et al. Mid- to Late-Life trajectories of blood pressure and the risk of stroke: the Rotterdam study. Hypertension. 2016;67(6):1126–32.CrossRefPubMed

54.

van Waateringe RP, Slagter SN, van Beek AP, van der Klauw MM, van Vliet-Ostaptchouk JV, Graaff R, et al. Skin autofluorescence, a non-invasive biomarker for advanced glycation end products, is associated with the metabolic syndrome and its individual components. Diabetol Metab Syndr. 2017. https://doi.org/10.1186/s13098-017-0241-1.CrossRefPubMedCentralPubMed

55.

Kochli S, Endes K, Trinkler M, Mondoux M, Zahner L, Hanssen H. Association of physical fitness with skin autofluorescence-derived advanced glycation end products in children. Pediatr Res. 2020;87(6):1106–11.CrossRefPubMed

56.

Gubbels Bupp MR. Sex, the aging immune system, and chronic disease. Cell Immunol. 2015;294(2):102–10.CrossRefPubMed

57.

Naessen T, Rodriguez-Macias K. Menopausal estrogen therapy counteracts normal aging effects on intima thickness, media thickness and intima/media ratio in carotid and femoral arteries—an investigation using noninvasive high-frequency ultrasound. Atherosclerosis. 2006;189(2):387–92.CrossRefPubMed

58.

Juonala M, Kahonen M, Laitinen T, Hutri-Kahonen N, Jokinen E, Taittonen L, et al. Effect of age and sex on carotid intima-media thickness, elasticity and brachial endothelial function in healthy adults: the cardiovascular risk in Young Finns Study. Eur Heart J. 2008;29(9):1198–206.CrossRefPubMed

59.

Sinning C, Wild PS, Echevarria FM, Wilde S, Schnabel R, Lubos E, et al. Sex differences in early carotid atherosclerosis (from the community-based Gutenberg-Heart Study). Am J Cardiol. 2011;107(12):1841–7.CrossRefPubMed

60.

Shardlow A, McIntyre NJ, Kolhe NV, Nellums LB, Fluck RJ, McIntyre CW, et al. The association of skin autofluorescence with cardiovascular events and all-cause mortality in persons with chronic kidney disease stage 3: A prospective cohort study. Plos Med. 2020;17(7):e1003163.PubMedCentralCrossRefPubMed

Title: Advanced glycation end products measured by skin autofluorescence and subclinical cardiovascular disease: the Rotterdam Study
Authors: Jinluan Chen
Banafsheh Arshi
Komal Waqas
Tianqi Lu
Daniel Bos
M. Arfan Ikram
André G. Uitterlinden
Maryam Kavousi
M. Carola Zillikens
Publication date: 01-12-2023
Publisher: BioMed Central
Published in: Cardiovascular Diabetology / Issue 1/2023
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-023-02052-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2023

Extended-release metformin improves cognitive impairment in frail older women with hypertension and diabetes: preliminary results from the LEOPARDESS Study

Primary aldosteronism and lower-extremity arterial disease: a two-sample Mendelian randomization study

Subclinical left ventricular deformation and microvascular dysfunction in T2DM patients with and without peripheral neuropathy: assessed by 3.0 T cardiac magnetic resonance imaging

The impact of the stress hyperglycemia ratio on mortality and rehospitalization rate in patients with acute decompensated heart failure and diabetes

Elevated plasma factor XI predicts cardiovascular events in patients with type 2 diabetes: a long-term observational study

Prognostic significance of plasma SDF-1 in acute ischemic stroke patients with diabetes mellitus: the CATIS trial

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials